Oncotelic Therapeutics, Inc. (OTLC)

USD 0.03

(0.0%)

Market Cap (In USD)

12.21 Million

Revenue (In USD)

70 Thousand

Net Income (In USD)

-7.9 Million

Avg. Volume

181.86 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.02-0.05
PE
-
EPS
-
Beta Value
-0.287
ISIN
US6283411097
CUSIP
628341109
CIK
908259
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vuong Trieu Ph.D.
Employee Count
-
Website
https://www.oncotelic.com
Ipo Date
1993-08-26
Details
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.